[Articles] Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial

Di |2025-01-16T00:30:01+01:00Gennaio 16th, 2025|Categorie: Coronavirus Lancet|

SPAQ and dihydroartemisinin–piperaquine effectively reduced malaria in children younger than 5 years, with no safety concerns. There was no evidence of resistance selection by SMC. Although these findings support SPAQ-based SMC in Eastern and Southern ...

[Articles] Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study

Di |2025-01-15T00:30:02+01:00Gennaio 15th, 2025|Categorie: Coronavirus Lancet|

The coprimary endpoints were met, and NVX-CoV2601 was well tolerated. These interim data support NVX-CoV2601 use per guidance for XBB.1.5-directed COVID-19 vaccines and demonstrate the adaptability of this vaccine platform for updated SARS-CoV-2 spike ...

[Comment] Efficacy of 8-aminoquinolines for Plasmodium vivax malaria radical cure: only one part of the problem

Di |2025-01-14T00:30:08+01:00Gennaio 14th, 2025|Categorie: Coronavirus Lancet|

It became clear after the last call for malaria elimination in 2007 that Plasmodium vivax malaria would be a substantial bottleneck because of many evolutive advantages of this parasite, such as the early development of peripheral gametocytes and the d...

[Articles] Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics

Di |2025-01-14T00:30:02+01:00Gennaio 14th, 2025|Categorie: Coronavirus Lancet|

Substantial reductions in prevalence as measured by PCR were predicted with primaquine and tafenoquine regimens if these could be implemented with high coverage and adherence. The benefits of preventing P vivax relapses need to be balanced against the ...

[Articles] Albendazole–ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial

Di |2025-01-11T00:30:01+01:00Gennaio 11th, 2025|Categorie: Coronavirus Lancet|

An FDC of albendazole plus ivermectin has a similar safety profile but superior efficacy to albendazole alone against T trichiura infection and hookworms. These findings open opportunities for control of all soil-transmitted helminth species of interes...

[Articles] Effect of mass drug administration on malaria incidence in southeast Senegal during 2020–22: a two-arm, open-label, cluster-randomised controlled trial

Di |2025-01-10T00:30:02+01:00Gennaio 10th, 2025|Categorie: Coronavirus Lancet|

In southeast Senegal, a low-to-moderate transmission setting where malaria-control measures have been scaled up, three cycles of MDA with dihydroartemisinin–piperaquine plus single, low-dose primaquine was safe and reduced malaria burden during the int...

[Corrections] Correction to Lancet Infect Dis 2024; published online Dec 16. https://doi.org/10.1016/S1473-3099(24)00648-0

Di |2025-01-09T00:30:02+01:00Gennaio 9th, 2025|Categorie: Coronavirus Lancet|

Shields RK, Abbo LM, Ackley R, et al. Effectiveness of ceftazidime–avibactam versus ceftolozanetazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Di...

[Corrections] Correction to Lancet Infect Dis 2024; published online Dec 18. https://doi.org/10.1016/S1473-3099(24)00730-8

Di |2025-01-09T00:30:01+01:00Gennaio 9th, 2025|Categorie: Coronavirus Lancet|

Dondorp AM. MMV533, a promising new antimalarial on the horizon. Lancet Infect Dis 2024; published online Dec 18. https://doi.org/10.1016/S1473-3099(24)00730-8—In this Comment, the fourth sentence of the second paragraph should read “…at 20 mg, which i...

Torna in cima